import type { Metadata } from 'next'
import { SectorDividendLanding } from '@/components/seo/SectorDividendLanding'
import { getSectorApiNameBySlug } from '@/lib/sector-mapping'

const PAGE_URL = 'https://dividendvisual.com/best-healthcare-dividend-stocks'
const YEAR = 2026
const DB_SECTOR = getSectorApiNameBySlug('healthcare') ?? 'Healthcare'

export const metadata: Metadata = {
  title: `Best Healthcare Dividend Stocks ${YEAR}: Safety & Yield`,
  description:
    'Compare healthcare dividend stocks like JNJ, ABBV, and BDX by yield, payout safety, dividend streak, and Weiss value signals for 2026 income ideas.',
  alternates: {
    canonical: PAGE_URL,
  },
  openGraph: {
    title: `Best Healthcare Dividend Stocks ${YEAR} | DividendVisual`,
    description:
      'Compare healthcare dividend stocks by yield, dividend safety, payout ratio, dividend growth, quality score, and Weiss valuation signal.',
    url: PAGE_URL,
    type: 'article',
  },
  twitter: {
    card: 'summary_large_image',
    title: `Best Healthcare Dividend Stocks ${YEAR} | DividendVisual`,
    description: 'Healthcare dividend stocks ranked by safety, growth, quality, and Weiss valuation signal.',
  },
}

export default function BestHealthcareDividendStocksPage() {
  return (
    <SectorDividendLanding
      pageUrl={PAGE_URL}
      eventName="best_healthcare_dividend_stocks_viewed"
      source="best-healthcare-dividend-stocks"
      dbSector={DB_SECTOR}
      eyebrow="Defensive healthcare income stocks"
      title={`Best Healthcare Dividend Stocks ${YEAR}`}
      description="Compare healthcare dividend stocks by dividend yield, payout safety, dividend growth, quality score, and Geraldine Weiss valuation signal. Built for long-term income investors evaluating pharma, medical devices, managed care, and healthcare services."
      statLabel="Healthcare stocks"
      ctaTitle="Get alerts when healthcare dividend stocks become undervalued"
      ctaDescription="A weekly dividend research email with healthcare and other quality defensive stocks entering historically attractive Weiss yield territory."
      featuredAnalyses={[
        {
          href: '/analysis/abbv',
          symbol: 'ABBV',
          title: 'AbbVie dividend history, yield, and Humira transition risk',
          note: 'Use the Weiss setup with payout coverage and pipeline context before treating the higher yield as a clean entry signal.',
        },
        {
          href: '/analysis/bdx',
          symbol: 'BDX',
          title: 'Becton Dickinson dividend quality and yield history',
          note: 'A device and diagnostics dividend profile where recurring demand, payout safety, and dividend growth matter more than headline yield.',
        },
      ]}
      relatedLinks={[
        { href: '/dividend-aristocrats', label: 'Dividend Aristocrats' },
        { href: '/dividend-kings', label: 'Dividend Kings' },
        { href: '/compare/jnj-vs-abbv', label: 'JNJ vs ABBV comparison' },
        { href: '/compare/unh-vs-cvs', label: 'UNH vs CVS comparison' },
        { href: '/blog/best-healthcare-dividend-stocks-2026', label: 'Healthcare dividend stock guide' },
        { href: '/dividend-screener', label: 'Dividend stock screener' },
      ]}
      sections={[
        {
          heading: 'How to evaluate healthcare dividend stocks',
          paragraphs: [
            'Healthcare is defensive, but it is not one single business model. Pharmaceuticals, medical devices, diagnostics, managed care, and distribution all have different dividend risk profiles.',
            'For dividend investors, the key is separating durable cash-flow franchises from companies facing patent cliffs, reimbursement pressure, litigation, or pipeline risk. A strong healthcare dividend usually combines diversification, conservative payout coverage, and a long record of annual increases.',
            'The first step is understanding the revenue model. A medical device company like Becton Dickinson earns from consumables used in millions of procedures daily — that is recurring, predictable, and relatively inelastic. A pharmaceutical company earning 60% of revenue from a single drug facing patent expiry in three years is a fundamentally different income risk.',
          ],
        },
        {
          heading: 'Why healthcare works with the Weiss method',
          paragraphs: [
            'Many large healthcare dividend stocks have long enough histories for yield-based valuation to be useful. When a high-quality healthcare company trades near the high end of its historical dividend yield range, the market may be pricing in temporary sector fear rather than permanent business impairment.',
            'The strongest setups pair an Undervalued Weiss signal with a quality score that confirms payout safety. This matters in healthcare because an elevated yield can also reflect real concerns about drug exclusivity, regulatory pricing, or falling cash flow.',
            'Healthcare sectors with the longest dividend histories — medical devices, diagnostics, and diversified pharmaceutical companies — tend to produce the most reliable Weiss signals. These are businesses where the dividend has survived multiple product cycles, generic competition waves, and regulatory changes, giving the historical yield range more predictive weight.',
          ],
        },
        {
          heading: 'Device and services compounders vs pharma income',
          paragraphs: [
            'Medical device and healthcare services companies often produce smoother cash flows than single-drug pharmaceutical companies. Recurring procedures, consumables, installed equipment bases, and insurance/service contracts create more predictable dividend funding.',
            'Pharmaceutical companies can still be excellent dividend stocks, but they require more monitoring. Patent cliffs, clinical trial failures, and pricing reform can change the cash-flow outlook faster than in consumer staples or utilities.',
            'Becton Dickinson, Stryker, and Abbott Laboratories represent the device/services model: their revenue comes from equipment, consumables, and lab services used every day in hospitals worldwide. Johnson & Johnson operated the same model at scale before its pharmaceutical and consumer health splits. These businesses generate free cash flow that grows modestly but reliably, which is the foundation of a compounding dividend.',
          ],
        },
        {
          heading: 'Pharmaceutical patent risk: understanding the dividend cliff',
          paragraphs: [
            'Pharmaceutical dividends depend on the product portfolio. A company earning most of its free cash flow from one or two blockbuster drugs faces a cliff when those patents expire and generic competition enters. AbbVie\'s Humira transition is the most prominent recent example — Humira generated over $20 billion in annual revenue before biosimilar competition, and the transition to a new product mix required investors to evaluate whether the replacement portfolio could sustain the dividend.',
            'Companies with diverse pipelines across multiple therapeutic areas reduce this cliff risk. Johnson & Johnson, Merck, and Eli Lilly have historically maintained dividends through patent expirations because the portfolio is broad enough that no single drug losing exclusivity causes a funding crisis.',
            'The quality score on pharmaceutical stocks at DividendVisual reflects payout coverage and dividend growth rate, which captures some of this pipeline risk indirectly. A pharmaceutical company with a high quality score and an Undervalued Weiss signal is telling you the dividend looks well-covered and the stock is historically cheap — but supplementing with pipeline research before acting on the signal is warranted.',
          ],
        },
        {
          heading: 'JNJ, ABT, BDX, SYK: the healthcare Dividend Aristocrats',
          paragraphs: [
            'Johnson & Johnson maintained over 60 consecutive years of dividend increases before its pharma and consumer splits. Abbott Laboratories has over 50 years of consecutive increases. Becton Dickinson has over 50 years. Stryker has raised its dividend for over 30 consecutive years with a 5-year CAGR among the highest in the sector.',
            'These records are earned through business model resilience, conservative payout ratios, and financial discipline. None of these companies paid out more than 70–80% of free cash flow in most years, leaving room to maintain the streak during difficult product cycles or acquisition integration periods.',
            'For Weiss investors, the combination of long history and conservative coverage gives these stocks among the highest-confidence signals in the healthcare universe. A quality score of 75+ combined with a Weiss undervalue signal in a company like ABT or BDX is one of the higher-probability setups in the screener.',
          ],
        },
        {
          heading: 'Managed care and healthcare distribution: volume-driven income',
          paragraphs: [
            'Managed care companies like UnitedHealth Group operate health insurance and healthcare services businesses at enormous scale. Revenue grows with membership, medical cost trends, and service expansion. The dividend is funded by operating cash flow that is relatively independent of pharmaceutical patent cycles or medical device innovation.',
            'Healthcare distributors like McKesson move pharmaceutical products through the supply chain. Margins are thin but volumes are enormous and recurring. These are not traditional income stocks by yield — both UNH and MCK tend to yield under 2% — but they offer dividend growth funded by essential infrastructure roles in the healthcare system.',
            'For income investors, managed care and distribution are useful portfolio diversifiers because their dividend risk is tied to enrollment trends and supply chain volumes rather than clinical development risk. They are typically better suited to the DRIP compounder thesis than the high-yield income thesis.',
          ],
        },
        {
          heading: 'Reading a healthcare yield spike: opportunity or deterioration?',
          paragraphs: [
            'When a healthcare dividend stock spikes to a historically high yield, the market is telling you something. The question is what. Sector-wide fear — regulatory pricing reform, Medicare reimbursement cuts, or generalist rotation out of defensive sectors — affects all healthcare stocks simultaneously and often creates temporary mispricings in high-quality names.',
            'Company-specific deterioration is different. A patent cliff hitting earnings, a failed drug trial, an adverse court ruling, or management guidance for lower cash flow can all push a yield to historical highs for fundamental reasons. These are not automatically bad investments, but they require more work than a sector-rotation-driven yield spike.',
            'The Weiss signal combined with the quality score helps separate these scenarios. If the quality score is still high — meaning payout ratio, dividend streak, and free cash flow coverage are intact — while the Weiss signal shows the stock is undervalued, the probability of a temporary mispricing is higher. If the quality score has declined alongside the signal, the elevated yield may be pricing in legitimate risk.',
          ],
        },
        {
          heading: 'Common questions about healthcare dividend stocks',
          paragraphs: [
            'Which healthcare stocks pay the best dividends? For dividend growth, Stryker, Abbott, and Becton Dickinson have long growth streaks with conservative payout ratios. For higher starting yield with more complexity, AbbVie and Pfizer offer elevated income with more business model-specific risk to evaluate.',
            'Are healthcare stocks defensive? Healthcare demand is relatively inelastic — people need medical care regardless of economic cycles. But healthcare stocks are not without risk. Government reimbursement changes, litigation, patent cliffs, and pricing reform can affect earnings even when volumes remain stable.',
            'How does dividend payout ratio work in healthcare? Most healthcare companies use earnings-based payout ratios, and a ratio under 60% is generally considered conservative for the sector. Pharmaceutical companies may show higher ratios during heavy pipeline investment years; medical device companies with recurring revenue tend to have more stable coverage ratios. Free cash flow coverage is often a cleaner metric than earnings-based payout.',
          ],
        },
      ]}
      checklist={[
        'Dividend is covered by earnings or free cash flow.',
        'Patent cliff or regulatory risk does not dominate the thesis.',
        'Dividend growth remains positive and sustainable.',
        'Quality score confirms payout durability.',
        'Weiss signal shows the entry yield is attractive versus history.',
      ]}
      faq={[
        {
          question: 'What are the best healthcare dividend stocks?',
          answer: 'The best healthcare dividend stocks usually combine durable medical demand, conservative payout ratios, recurring cash flow, and long dividend growth records. Examples often include diversified pharma, medical device, diagnostics, managed care, and healthcare distribution companies.',
        },
        {
          question: 'Are healthcare dividend stocks defensive?',
          answer: 'Healthcare demand is relatively defensive because patients need treatment through economic cycles. Individual healthcare stocks still carry risks from patent expirations, clinical trial failures, pricing regulation, reimbursement pressure, and litigation.',
        },
        {
          question: 'How should investors compare JNJ and ABBV?',
          answer: 'JNJ is usually the steadier lower-yield healthcare dividend profile, while ABBV offers a higher yield with more product-cycle and pipeline risk. Comparing payout coverage, dividend growth, and Humira replacement progress is more useful than yield alone.',
        },
        {
          question: 'What payout ratio is safe for healthcare dividend stocks?',
          answer: 'A payout ratio below roughly 60% is generally conservative for large healthcare dividend stocks, but the right threshold depends on business mix. Medical device companies often have steadier cash flow, while pharmaceutical companies require more pipeline and patent-risk analysis.',
        },
      ]}
    />
  )
}
